Free Access

Tableau II.

Molécules ciblant des miARN actuellement en cours d’essais cliniques.

Nom de la molécule Nom de la compagnie pharmaceutique Type de molécule/ miARN cible Maladie cible
Miravirsen Santaris pharma puis Roche antimiR-122 Hépatite C

RG-101 Regulus Therapeutics antimiR-122 Hépatite C

RG-125/AZD4076 Regulus Therapeutics antimiR-103/107 Diabète de type 2

MRG-106 miRagen Therapeutics antimiR-155 Lymphome cutané à cellules T

MRG-201 miRagen Therapeutics mimic miR-29 Sclérodermie

MesomiR-1 EnGeneIC mimic miR-16 Mésothéliome

MRX34 miRNA therapeutics mimic miR-34 Tumeurs solides multiples

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.